See the DrugPatentWatch profile for cosentyx

The recommended dosage adjustment schedule for Cosentyx (secukinumab) can vary depending on the patient's weight, kidney function, and the specific medical condition being treated. However, according to the Cosentyx prescribing information provided by the FDA, the following general dosage recommendations apply:

* For adult patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, or ankylosing spondylitis, the recommended dosage is 300 mg (as two 150 mg injections) at Weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.
* For adult patients with active enthesitis-related arthritis or non-radiographic axial spondyloarthritis, the recommended dosage is 150 mg at Weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks.

It's important to note that these are general recommendations, and the dosage may need to be adjusted based on individual patient characteristics and response to treatment. Additionally, patients with severe renal impairment may require dose adjustments or more frequent monitoring.

For the most up-to-date and personalized dosage information, patients should consult with their healthcare provider.

Sources:

1. Cosentyx (secukinumab) injection, for subcutaneous use [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2022. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
2. DrugPatentWatch. Cosentyx (secukinumab) Drug Profile. Available from: <https://www.drugpatentwatch.com/drugs/cosentyx>.